BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/11/2014 9:29:00 AM | Browse: 1066 | Download: 940
Publication Name World Journal of Nephrology
Manuscript ID 3882
Country India
Received
2013-05-30 08:10
Peer-Review Started
2013-05-30 09:42
To Make the First Decision
2013-06-24 10:24
Return for Revision
2013-07-04 14:43
Revised
Second Decision
2014-03-04 09:52
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-03-04 10:16
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
2014-03-13 17:31
Typeset the Manuscript
2014-05-08 20:22
Publish the Manuscript Online
2014-05-19 21:10
ISSN 2220-6124 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Pediatrics
Manuscript Type Minireviews
Article Title Pediatric lupus nephritis: Management update
Manuscript Source Invited Manuscript
All Author List Rajiv Sinha and Sumantra Raut
Funding Agency and Grant Number
Corresponding Author Dr. Rajiv Sinha, PhD, Division of Pediatric Nephrology, Department of Pediatrics, Institute of Child Health, 11 Biresh Guha Street, Kolkata 700017, India. rajivsinha_in@yahoo.com
Key Words Pediatric; Lupus nephritis; Management; Monoclonal antibody; Cyclophosphamide; Mycophenolate mofetil
Core Tip Childhood-onset systemic lupus erythematosus (cSLE) is a rare but severe autoimmune disease with multisystem involvement. Renal disease occurs in 50% to 75% of all cSLE patients and is a major cause of increased morbidity and mortality. Originally SLE nephritis was treated with steroids with a poor outcome which improved markedly with the introduction of cyclophosphamide, but at the cost of increased side effects which resulted in a further search for a less toxic, but equally effective regime. Here we discuss some newer drugs including immune-modulators and monoclonal antibodies in addition to azathioprine and mycophenolate mofetil, however, most of the evidence on these medications is restricted to adult literature and pediatric data are extrapolated from these trials.
Publish Date 2014-05-19 21:10
Citation Sinha R, Raut S. Pediatric lupus nephritis: Management update.World J Nephrol 2014; 3(2): 16-23
URL http://www.wjgnet.com/2220-6124/full/v3/i2/16.htm
DOI http://dx.doi.org/10.5527/wjn.v3.i2.16
Full Article (PDF) WJN-3-16.pdf
Full Article (Word) WJN-3-16.doc
Manuscript File 3882-Review.doc
Answering Reviewers 3882-Answering reviewers.pdf
Copyright License Agreement 3882-Copyright assignment.pdf
Peer-review Report 3882-Peer reviews.pdf
Scientific Editor Work List 3882-Scientific editor work list.doc